Fluidigm Shares Gain As Preliminary Q4, FY21 Sales Exceed Expectations


Fluidigm Corp FLDM expects Q4 FY21 sales of $38.0 million - $38.3 million, exceeding the company's prior guidance of $31 million – $34 million and the analyst estimate of $32.7 million.

  • Base product and service revenue, excluding COVID-19 testing, is expected to be $35.1 million - $35.4 million, +13%–14% Y/Y.
  • Mass Cytometry product and service revenue is anticipated to increase 8% - 9% to $21.0 million - $21.2 million. Base Microfluidics product and service revenue is expected to reach $14.1 million - $14.2 million.
  • Related: Fluidigm Q3 Sales Trail Estimates; Cuts Annual Guidance As COVID-19 Sales Retreat.
  • For FY21, the company forecasts total revenue of $130.3 million - $130.6 million, exceeding previous guidance of $123 million –$127 million and beating the estimate of $125 million.
  • "Core demand for our products remained healthy during the quarter. Supply chain issues were partially resolved, and we were able to meet a significant portion of this demand," said Chris Linthwaite, President and CEO. 
  • Price Action: FLDM shares are up 2.67% at $3.27 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: EarningsNewsPenny StocksGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!